To establish whether targeting of the Wnt signaling pathway at the level of the ligand/receptor would be therapeutically beneficial for GC, we recently published a paper identifying that pharmacologically targeting Fzd receptors or specific genetic deletion of Fzd7 inhibited the initiation and growth of gastric tumors in vitro and in vivo [31]. This evidence concerns the gene FZD7 and gastric neoplasm.